he purpose of this study is to better characterize how a
marketed Biogen multiple sclerosis (MS) product specified
in this Pregnancy Registry may affect pregnancy and infant
outcomes.
The primary objective of the study is to prospectively
evaluate pregnancy outcomes in women with MS who
were exposed to a Registry-specified Biogen MS product
during the eligibility window for that product.
The secondary objective of the study is to prospectively
evaluate pregnancy outcomes in women with MS who
were unexposed to disease-modifying therapies.